Thank you for your submission to EMBO reports. We have now received reports from the three referees that were asked to evaluate your study, which can be found at the end of this email. As you will see, all the referees find the topic of interest and the study in principle suitable for us, although they all raise a number of concerns that need to be addressed before we can consider your study further.
Thank you for your submission to EMBO reports. We have now received reports from the three referees that were asked to evaluate your study, which can be found at the end of this email. As you will see, all the referees find the topic of interest and the study in principle suitable for us, although they all raise a number of concerns that need to be addressed before we can consider your study further.
Given that all referees provide constructive suggestions on how to strengthen the work, I would like to give you the opportunity to revise your manuscript. A clear issue that has dimished enthusiasm for the study is that your approach identifies not only E3 ligase substrates but other potential interactors; this needs to be made clearer and openly discussed, as well as standards/guidelines provided, as suggested by referee #3. All referee concerns are partinent and should be addressed. Of particular importance is to validate the target binding site through site-directed mutagenesis and to provide verification for a subset of the novel interactors identified, in addition to other controls and additional discussions requested.
If the referee concerns can be adequately addressed, we would be happy to consider your manuscript for publication. Please note that it is EMBO reports policy to undergo one round of revision only and thus, acceptance of your study will depend on the outcome of the next, final round of peerreview.
Revised manuscripts must be submitted within three months of a request for revision unless previously discussed with the editor; they will otherwise be treated as new submissions.
I look forward to seeing a revised form of your manuscript when it is ready. In the meantime, please contact me if I can be of any assistance.
REFEREE REPORTS:
Referee #1:
O'Connor et al. present an innovative new strategy for trapping and identifying substrates and interacting proteins of E3 ubiquitin ligases. E3:substrate interactions are often weak and transient, making the task of identifying targets for any given ligase difficult.
In their work, the authors describe a new method to covalently trap substrates to the E3 ligase by fusing ubiquitin to the E3 C-terminus. Although this strategy was originally intended to function through a lariat intermediate at the HECT active site, the authors find that this strategy also works for RING E3s, and presumably any protein. This added functionality for the HUTT strategy (ie RUTTs and PUTTs) presumably works because the C-terminal Ub fusion is activated by an E2 conjugating enzyme in cells, then nonspecifically ligated onto a nearby target protein; if the protein binds other proteins transiently or is in a complex, such interacting proteins will be preferred substrates.
Although this parallel mechanism observed in the RUTTs and catalytically inactive HUTTs distract somewhat from the notion of specifically identifying E3 ligase substrates (though these will also be in the list of e.g. HUTTylated proteins), it also expands the possibilities of using this approach for any protein.
The novelty of this approach combined with the possibilities it opens up makes this a very exciting study. The strategy is tested for several E3 ligases, with appropriate controls for each, and in every case an impressive number of previously reported as well as novel, yet sensible, interacting proteins are identified. With only a few minor comments detailed below, this reviewer is happy to recommend publication in EMBO Reports.
1. How do you explain the multi-HUTTylation observed in the case of Rsp5 with Sna3, considering this is a single Lys variant? Tagged ubiquitins can usually for nice polymers, and in particular with HECTs these are assembled in a linkage-specific fashion. Can HUTTs/RUTTs still be in polymers? This should be discussed. Indeed, if this was the case, it could help to validate substrates. 2. Considering the HUTTylation observed using the catalytically inactive Rsp5 in vitro is most likely nonspecific Lys modification directly from the E2, would you expect this to still be an issue if you swapped out the E2 for UbcH7 that should only function through the lariat mechanism? 3. A nice control for your in vitro experiments would be addition of substrates in which the PY motifs are mutated. 4. The use of "target" in the title and abstract implies a ubiquitination substrate and is thus somewhat misleading, as substrates cannot be distinguished from interacting proteins in the current setup. In general, the separation between actual substrates and non-covalently interacting proteins should be made more clearly. 5. In the in vitro assays, only a small fraction of the HUTTs/RUTTs is modified with a substrate. It may be helpful to include a control at a later time point or with a bigger excess of substrate to show that the reaction can be driven to completion. 6. Please state in the methods explicitly which affinity tags the tandem affinity tag in this study consists of. 7. For completeness, the authors should at least mention the mechanistically distinct RBRs in the introduction.
Referee #2:
O'Connor et al. describe a new method to identify targets of HECT and RING ubiquitin ligases, named HUTTs and RUTTs, respectively, which involves fusion of a ligase to the N-terminus of ubiquitin. This allows the free ubiquitin C-terminal end to be conjugated to proteins that interact with the ligase (i.e. substrates) via an amide linkage, enabling their subsequent copurification and identification by LC-MS/MS. The authors provide experiments both in vitro and in vivo using yeast and human cells to demonstrate that this technique can capture known and novel interactors of the Rsp5, Itch, Psh1, and Rnf126 ligases. Analysis of the Rsp5 HUTT identified ~30% of the known interactors of this ligase, while the Itch HUTT captured numerous proteins involved in endocytosis (a process it is known to mediate). The Psh1 RUTT identified its sole known substrate, Cse4, and the Rnf126 RUTT captured one of three members of the known interacting Bag6 complex.
There is a strong positive and a strong negative component to this manuscript. The strong positive is that the authors have come up with a novel strategy and implemented it over several ligases and organisms. In this sense the work is quite complete. The negative is that, while the title and abstract suggest that this method identifies substrates of ligases, the authors acknowledge that the data suggest it really identifies interactors. There are other technologies that do this, such as BioID, however, this could, arguably, improve upon those. The problem is that the authors don't go forward and examine their new interactors and therefore it is difficult to know if these are correct. The high number of known interactors in the group suggests that some of these might be real. If the authors had gone through and verified a set (chosen either at random, or by some explicit criterion), then this would be a nice paper, and I would accept it for EMBO reports or EMBO J. However, without any follow-up it is hard to know. Some of these data look nice and could prove very useful to those working on these proteins, but only verification can really prove this.
Referee #3:
The ability to identify substrates of a given E3 ubiquitin ligase remains one of the field's greatest challenges. The manuscript " HECT-and RING-Ubiquitin Target Traps: Tools for Profiling Ubiquitin Ligases" presents a strategy aimed at this challenge. Tethering of Ubiquitin to the Cterminus of a HECT-or RING-domain E3 yields a fusion protein in which the ubiquitin moiety can still be activated by an E1, transferred to an E2, and covalently attached to protein targets or other proteins associated with the E3 ligase. These fusion proteins, called HUTTs and RUTTs for HECTtype and RING-type fusions respectively, are essentially enzymatic cross-linking reagents that putatively retain sufficient activity and selectivity to identify potential intracellular targets of the E3.
The approach seems particularly amenable to investigate intracellular ubiquitin signaling of HECT E3 ligases. These enzymes have a common architecture with substrate binding regions positioned Nterminal to the C-terminal ligase domain. The authors do a good job of exploring the various ways the system might work to covalently tag target proteins. An assumption underlying the utility of the approach is the requirement for a target-binding site that allows for selective modification. However, explicit confirmation of this assumption is missing. A comparison of the in vitro efficiency of HUTT modification when the RSP5 and/or ITCH substrate binding sites are eliminated by point mutations would provide stronger evidence that the reagents work as designed rather than merely adventitious.
The question of an intact substrate-binding site is particularly thorny for application of RUTTs. RING-type E3s are much more diverse in their protein architecture. The RING domain can be positioned at various locations within a single protein, or be part of large protein complexes. For RINGs that are part of a single polypeptide chain the substrate-binding site is generally not known. And RING-type E3s are often very large polypeptides with long intrinsically disordered regions. All these features will likely make the RUTT approach more hit-and-miss. In this respect, the authors' choice of a C-terminal RING domain (Rnf126) may have been a particularly good one. At the very least, the authors should present and discuss these issues. However in this reviewers' opinion, the extremely low in vitro modification efficiencies presented for RUTTs in the manuscript is underwhelming ( Figure S6 ). The paper would have higher impact if it focused primarily on application of HUTTs to identify intracellular targets as these constructs are more likely to produce fruit.
Finally, while the HUTT approach provides some selectivity in identifying ubiquitination targets, it is not necessarily absolute. As the authors point out, proteins that associate with an E3 and are located near the E2~Ub-HUTT may be trapped by covalent modification, even if they are not true targets for ubiquitination. The authors show that comparison of proteins trapped by covalent and non-covalent associations can be helpful in differentiating these possibilities but this may not work in all cases, as shown by the differences between Rsp5 and Itch. These issues will be particularly difficult to interpret for HECT E3s that are not as well characterized as Rsp5. Nonetheless, identifying both targets and proteins that form a complex with an E3 can provide valuable functional information. Presumably the authors hope that others will adopt the HUTT methodology. It would therefore be helpful for the authors to discuss guidelines and/or standards that could be used to differentiate the two cases and to validate putative targets.
1st Revision -authors' response 26 July 2015
We thank the Editor and the reviewers for their comments and suggestions. We preface our responses by pointing out two significant alterations, one of which has been to change the name of the reagents from HUTTs, RUTTs, and PUTTs (HECT, RING and general PROTEIN-Ubiquitin Target Traps), to UBAITs, for Ubiquitin-Activated Interaction Traps. This change provides a single simplified terminology, regardless of the bait protein.
In addition, the new terminology emphasizes the trapping of interacting proteins, broadly, rather than just "targets" (i.e., enzyme substrates). As the reviewers correctly pointed out, our approach identifies both substrates and regulatory and other interacting proteins, which is a strength of the approach.
A second major change in the manuscript is that we have now analyzed human RNF168 with the UBAIT approach, and this has identified a novel substrate of this RING E3, histone H2AZ. This has been validated both in cells and in vitro, and we are confident that this result will be of significant interest to those in the DNA repair field. We believe this addition addresses the concern that the manuscript was focused solely on proof of principal demonstrations (i.e., isolating known substrates), without discovery and validation of new targets.
Referee #1:
O This issue is addressed on page 7 of the manuscript. The UBAITylation reactions are essentially single-turnover reactions (as discussed further under point 5, below), so ubiquitin or UBAIT polymers cannot be built in the typical sense. On the other hand, in some cases we do observe di-or even tri-UBAITylated targets in vitro; we think the most parsimonious explanation for a di-UBAITylated Rsp5 target proteins is that the PY motif of a mono-UBAITylated protein can re-bind to the WW domains of a second UBAIT molecule, and then be doubly-modified. In addition, once a target is mono-UBAITylated, the fact that the initial target protein might have had a single lysine is no longer relevant, as there are many lysines on the UBAIT that can serve as potential acceptors for a second UBAIT molecule.
Considering the HUTTylation observed using the catalytically inactive Rsp5 in vitro is most likely nonspecific Lys modification directly from the E2, would you expect this to still be an issue if you swapped out the E2 for UbcH7 that should only function through the lariat mechanism?
We had the same thought, and found that UbcH7 (which was reported to only discharge to cysteines and not lysines) still allowed for some trapping of substrates in vitro with the C-A mutant UBAIT, albeit less efficiently than Ubc1 (which can discharge to both cysteines and lysines). While not disputing the published results from the Klevit lab on the biochemical properties of UbcH7, we believe we observed these results because UbcH7 does in fact have a low ability to discharge to lysines in vitro. We chose to avoid the issue and did not present the data, particularly since the non-lariat mechanism was shown to predominate in cells.
3. A nice control for your in vitro experiments would be addition of substrates in which the PY motifs are mutated. Figure S1) showing that the PY-mutant form of Sna3 is not trapped by the WT Rsp5 UBAIT in vitro. In addition, a specific mutation in the acidic patch of histone HA2Z is shown to lead to loss of in vitro RNF168 ubiquitylation.
Thank you for this suggestion. We have now included a new supplemental figure (Appendix
4. The use of "target" in the title and abstract implies a ubiquitination substrate and is thus somewhat misleading, as substrates cannot be distinguished from interacting proteins in the current setup. In general, the separation between actual substrates and non-covalently interacting proteins should be made more clearly.
As stated in the preface, the new acronym, UBAITs, was developed to avoid the inference that the method was specific for targets (i.e., substrates), as opposed to regulatory or other interacting proteins, broadly.
5. In the in vitro assays, only a small fraction of the HUTTs/RUTTs is modified with a substrate. It may be helpful to include a control at a later time point or with a bigger excess of substrate to show that the reaction can be driven to completion.
Increased time (beyond 1 hr) did not lead to further conjugation and we have not found conditions where the reaction can be driven to completion. As stated above, it is important to note that for the UBAITs, only 1 round of substrate modification can occur per UBAIT molecule (i.e., it is single turnover), while for Rsp5 (non-UBAIT), the same molecule of Rsp5 can catalyze many rounds of ubiquitylation of one substrate molecule, and then do the same to many additional substrate molecules over time. This explanation for the apparent inefficiency of the in vitro reaction is now discussed in the Results (top of page 8 of manuscript).
6. Please state in the methods explicitly which affinity tags the tandem affinity tag in this study consists of.
This omission has been corrected (see bottom of page 8 of manuscript).
7. For completeness, the authors should at least mention the mechanistically distinct RBRs in the introduction. This is now included in the Introduction.
Referee #2: O'Connor et al. describe a new method to identify targets of HECT and RING ubiquitin ligases, named HUTTs and RUTTs, respectively, which involves fusion of a ligase to the Nterminus of ubiquitin. This allows the free ubiquitin C-terminal end to be conjugated to proteins that interact with the ligase (i.e. substrates) via an amide linkage, enabling their subsequent copurification and identification by LC-MS/MS. The authors provide experiments both in vitro and in vivo using yeast and human cells to demonstrate that this technique can capture known and novel interactors of the Rsp5, Itch, Psh1, and Rnf126 ligases. Analysis of the Rsp5 HUTT identified ~30% of the known interactors of this ligase, while the Itch HUTT captured numerous proteins involved in endocytosis (a process it is known to mediate). The Psh1 RUTT identified its sole known substrate, Cse4, and the Rnf126 RUTT captured one of three members of the known interacting Bag6 complex.

There is a strong positive and a strong negative component to this manuscript. The strong positive is that the authors have come up with a novel strategy and implemented it over several ligases and organisms. In this sense the work is quite complete. The negative is that, while the title and abstract suggest that this method identifies substrates of ligases, the authors acknowledge that the data suggest it really identifies interactors. There are other technologies that do this, such as BioID, however, this could, arguably, improve upon those. The problem is that the authors don't go forward and examine their new interactors and therefore it is difficult to know if these are correct. The high number of known interactors in the group suggests that some of these might be real. If the authors had gone through and verified a set (chosen either at random, or by some explicit criterion), then this would be a nice paper, and I would accept it for EMBO reports or EMBO J. However, without any follow-up it is hard to know. Some of these data look nice and could prove very useful to those working on these proteins, but only verification can really prove this.
We thank the reviewer for these comments. As stated above, the change in the nomenclature to UBAITs was made to emphasize the fact that these reagents have the ability to trap both targets/substrates and other interacting proteins (a strength of the approach). We hope this is now sufficiently clarified. The other major addition is that we have analyzed RNF168 by the UBAIT approach and isolated the best-characterized target of RNF168 as well as a novel target, histone H2AZ; the latter was validated both in cells and in vitro as a target of RNF168 ubiquitylation activity. We believe this will be of considerable interest to those that study doublestranded DNA break repair and is therefore a significant addition to the manuscript.
Referee #3:
The ability to identify substrates of a given E3 ubiquitin ligase remains one of the field's greatest challenges. The manuscript " HECT-and RING-Ubiquitin Thank you for the comment regarding the target-binding site of substrates (similar to comment #3 from Reviewer 1). We have addressed this the requirement for an intact degron within the substrate in Appendix Figure S1 , showing that the Rsp5 UBAIT does not target Sna3 when the PY motif of Sna3 is disrupted by mutation. · Like many approaches developed over the years for identifying protein-protein interactors (e.g., two-hybrid, co-IPs, BioID, etc), we do not expect the UBAIT approach to be useful for all proteins of interest. That is, all such approaches are, to some extent, hit-or-miss. We do have confidence, however, that the UBAIT approach will be a valuable tool to many investigators. · Thank you for the comment concerning the structural diversity of RING E3s. While the RING domain of RNF126 is within the C-terminal portion of this protein, the RING domains of both yeast Psh1 and human RNF168 are located at the extreme N-termini of these proteins (which are 47 kD and 65 kD proteins, respectively). Therefore, at the point we do not think it can be predicted whether the UBAIT approach should be any more or less useful when applied to RING, compared to HECT, E3s. A statement regarding this has been added to the Discussion. · We concede that the levels of in vitro UBAITylation may appear underwhelming, however there are many factors that can influence this, some of which are specific may be specific to UBAITs (see responses to comments #1, and #5 from Reviewer 1, above), while others may be related to the challenge of many in vitro ubiquitylation reconstitutions. Nevertheless, while the real test of the approach is whether the UBAITs work in cells, the in vitro results presented are illuminating with respect to mechanism, particularly for the HECT E3 UBAITs and for RNF168. · Clearly, standards for analysis, similar to an approach like the yeast two-hybrid system, in every case the investigator must filter their results through their own knowledge and experience with their protein of interest. Just as there can be no absolute criteria in a two-hybrid assay as to what constitutes a bona fide interactor, we do not believe there can be strict criteria for UBAIT approach. We do believe that the five examples we've provided in the manuscript and the analyses as we've conducted them are likely to be representative of what other investigators are likely to encounter with the UBAIT system. Finally, concerning the covalent versus noncovalent isolations, one would certainly not want to throw out the non-covalent interactors, as these may very well represent bona fide interacting proteins. Thank you for the submission of your revised manuscript to our offices. We have now received the enclosed reports from the referees 1 and 2. Although referee 3 has not yet sent in his/her report, I am making a decision now to avoid unnecessary loss of time. As you will see, both referees are very positive about the study and request only minor changes to clarify text and figures.
From the editorial side, there are also a few things that we need before we can proceed with the official acceptance of your study.
-It is a precondition for publication in EMBO reports that authors agree to make all data freely available, where possible in an appropriate public database. In the case of mass spectrometry datasets, they should be deposited in a machine-readable format (e.g. mzML if possible) in one of the major public database, for example Pride (http://www.ebi.ac.uk/pride/) or PeptideAtlas(http://www.peptideatlas.org) and authors should follow the MIAPE recommendations (http://www.psidev.info/index.php?q=node/91).
Please deposit your data in one of these databases instead of including it in the Appendix, and provide the reference number in the manuscript.
-Your study will be published in article format. As such, all of the Materials and Methods must be included in the main text and cannot be part of the Appendix.
We look forward to seeing a final version of your manuscript as soon as possible.
REFEREE REPORTS:
This is an excellent piece of work, and the described method will be useful to many researchers. It is conceptually beautiful and clearly works. I cannot wait to get someone to try it.
The manuscript has been nicely improved, the change in nomenclature is a clever idea to address ambiguities, and the additional data on RNF168 and H2AZ are very exciting.
three comments a) p14; maybe exchange 'proximity' with 'distance' b) please add MW markers to gels in Fig 2a and Fig 3. c) Fig 2a : the * indicates a band that does not really make sense as its not clear what substrate is in this context? maybe I did not get it, but labelling it as contaminant may be more suitable?
I suggest the paper being published immediately, as is.
Referee #2:
While the analysis of H2AZ does not got far, it does provide support that the method developed is able to identify novel substrates. I feel that, with one minor correction, this manuscript is now suitable for publication.
In the figure legend for Figure 3A , the authors define a MIU and a UIM, whereas the motifs in question that are shown in the figure are a MIU and a UMI. This should be corrected. Thank you for your email (Aug. 19) regarding our manuscript. We have made the suggested minor changes from Reviewers 1 and 2, and we have deposited the complete mass spectrometry data on a public database. I am very pleased to accept your manuscript for publication in the next available issue of EMBO reports.
Thank you for your contribution to EMBO reports and congratulations on a successful publication. Please consider us again in the future for your most exciting work.
